Lilly cuts Germany investment plan in half over healthcare reforms

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. NVDA
9. CSCO
10. KTOS

Go back to Lilly cuts Germany investment plan in half over healthcare reforms

Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'

June 5, 2026 7:38 AM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,344.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Mounjaro TRx/NRx scripts for the week ending 5/29/26 were ~756,700/353,700 (vs. ~796,800/388,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were ~610,800/328,300 (vs. ~659,000/360,200 last week). We see ~7% upside to '26 M+Z ests. We are monitoring the launches of LLY's Mounjaro (injectable GLP-GIP) for type 2 diabetes (T2D), and Zepbound (injectable GLP-GIP) for obesity, and Foundayo (oral GLP) given these are the company's key product cycles. Total GLP-1 TRx (LLY+Novo) grew ~32% yoy (see... More